News

Deep Genomics has raised $180m funding in Series C financing round to expand its artificial intelligence (AI) discovery platform for ‘Programmable’ RNA therapeutics and scale its portfolio into

GlaxoSmithKline (GSK) and Vir Biotechnology have announced a joint procurement agreement with the European Commission for the supply of up to 220,000 doses of sotrovimab to treat Covid-19

AbbVie has extended its collaboration with Calico Life Sciences to discover and develop new therapies for patients with age-related diseases, including neurodegeneration and cancer. The two companies have

Biotechnology company Amgen has agreed to acquire Teneobio, a privately held clinical stage biotechnology firm, in a deal valued at about $900m. Teneobio is developing a new class

PerkinElmer has signed an agreement to acquire US-based BioLegend, a life science antibodies and reagents provider, in a deal valued at about $5.25bn. BioLegend provides antibodies and reagents

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Moderna’s Covid-19 vaccine, Spikevax, for adolescents aged 12 to 17

Merck and Eisai have secured approval from the US Food and Drug Administration (FDA) for Keytruda (pembrolizumab) plus Lenvima (lenvatinib) combination to treat patients with certain types of

Pfizer and Arvinas have collaborated to co-develop and co-commercialise ARV-471, an investigational oral Protac estrogen receptor protein degrader. The estrogen receptor (ER) is a well-known disease driver in

AstraZeneca has completed the acquisition of biopharmaceutical company Alexion Pharmaceuticals in a deal valued at $39bn. The latest move comes after the receipt of clearance from the UK